Document:

Amended and Restated Investors' Rights Agreement

 EXHIBIT 4.2 
  
 ACOLOGIX, INC. 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 
 June 29, 2006 

 TABLE OF CONTENTS 
  

							
	  	 	  	 	 	  	Page
	 1.Certain Definitions
	  	1
				
		 	 1.1
	 	 “Commission”
	  	1
		 	 1.2
	 	 “Conversion Stock”
	  	1
		 	 1.3
	 	 “Exchange Act”
	  	2
		 	 1.4
	 	 “Holder”
	  	2
		 	 1.5
	 	 “Registrable Securities”
	  	2
		 	 1.6
	 	 “Register,” “Registered” and “Registration”
	  	2
		 	 1.7
	 	 “Registration Expenses”
	  	2
		 	 1.8
	 	 “Restricted Securities”
	  	2
		 	 1.9
	 	 “Securities Act”
	  	2
		 	 1.10
	 	 “Selling Expenses”
	  	2
		 	 1.11
	 	 “Shares”
	  	2
		 	 1.12
	 	 “Warrants”
	  	3
		
	 2.Restrictions on Transfer; Compliance with Securities Act; Market Standoff
	  	3
				
		 	 2.1
	 	 Restrictions on Transfer
	  	3
		 	 2.2
	 	 Restrictive Legend
	  	3
		 	 2.3
	 	 Notice of Proposed Transfers
	  	4
		 	 2.4
	 	 Removal of Restrictions on Transfer of Securities
	  	4
		 	 2.5
	 	 Market Standoff Agreement
	  	4
		
	 3.Registration Rights
	  	5
				
		 	 3.1
	 	 Demand Registration
	  	5
		 	 3.2
	 	 Company Registration
	  	7
		 	 3.3
	 	 Registration on Form S-3
	  	8
		 	 3.4
	 	 Expenses of Registration
	  	9
		 	 3.5
	 	 Registration Procedures
	  	9
		 	 3.6
	 	 Indemnification
	  	10
		 	 3.7
	 	 Information by Holder
	  	12
		 	 3.8
	 	 Rule 144 Reporting
	  	12
		 	 3.9
	 	 Transfer of Registration Rights
	  	13
		 	 3.10
	 	 Termination of Registration Rights
	  	13
		 	 3.11
	 	 Limitations on Subsequent Registration Rights
	  	13
		
	 4.Investors’ Right of First Refusal
	  	13
				
		 	 4.1
	 	 Right of First Refusal
	  	13
		 	 4.2
	 	 New Securities
	  	14
		 	 4.3
	 	 Notice of Proposed Issuance
	  	14
		 	 4.4
	 	 Transfer of Rights
	  	14
		 	 4.5
	 	 Termination of Rights
	  	14
		 	 4.6
	 	 Existing Investor Waiver
	  	14
		
	 5.Affirmative Covenants
	  	15
				
		 	 5.1
	 	 Financial Information
	  	15

							
		 	 5.2
	 	 Inspection Rights
	  	15
		 	 5.3
	 	 Termination of Covenants
	  	16
		
	 6.Miscellaneous
	  	16
				
		 	 6.1
	 	 Waivers and Amendments
	  	16
		 	 6.2
	 	 Governing Law
	  	16
		 	 6.3
	 	 Successors and Assigns
	  	16
		 	 6.4
	 	 Entire Agreement
	  	16
		 	 6.5
	 	 Notices
	  	16
		 	 6.6
	 	 Titles and Subtitles
	  	17
		 	 6.7
	 	 Stock Splits, etc.
	  	17
		 	 6.8
	 	 Termination of Prior Agreement
	  	17
		 	 6.9
	 	 Counterparts
	  	17
		
	 Schedule:
	  	
				
	 A
	 	–	 	 Schedule of Investors
	  	

  

 ii 

 EXHIBIT 4.2 
 ACOLOGIX, INC. 
 AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 
 This Amended and Restated
Investors’ Rights Agreement (the “Agreement”) is made as of June 29, 2006 by and among Acologix, Inc., a Delaware corporation (the “Company”) and the individuals and entities listed on Schedule A
hereto (each, an “Investor” and collectively, the “Investors”). This Agreement amends, supersedes and replaces the Company’s Amended and Restated Investors’ Rights Agreement dated December 16, 2005
(the “Prior Agreement”). 
 RECITALS 
 WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Common Stock, Series A Preferred
Stock, Series A-1 Preferred Stock, Series B Preferred Stock and/or Series C Preferred Stock and possess registration rights, information rights, rights of first refusal and other rights pursuant to the Prior Agreement; 
 WHEREAS, the Existing Investors are holders of at least fifty percent (50%) of the Company’s Registrable Securities (as defined in the
Prior Agreement), and desire to terminate the Prior Agreement and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; 
 WHEREAS, the Company and Toray Industries, Inc. (“Toray”) entered into a Series C Preferred Stock Purchase Agreement dated on or
about June 12, 2006, in connection with which the Company has agreed to issue 490,196 shares of Series C Preferred Stock to Toray (the “Toray Purchase Agreement”); and 
 WHEREAS, the Company is obligated under the Toray Purchase Agreement to add Toray as a party to this Agreement with respect to the shares acquired
under the Toray Purchase Agreement, which addition requires the execution and delivery of this Agreement by the Company, Toray and the Existing Investors holding at least fifty percent (50%) of the Company’s Registrable Securities (as
defined in the Prior Agreement). 
 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, the
Existing Investors hereby agree that the Prior Agreement shall be superseded and replaced in its entirety by this Agreement, and the parties hereto further agree as follows: 
 1.     Certain Definitions.    As used in this Agreement, the following terms shall have the following
respective meanings: 
 1.1    “Commission” shall mean the U.S. Securities and Exchange Commission or
any other federal agency at the time administering the Securities Act. 
 1.2     “Conversion Stock”
shall mean the shares of Common Stock issued or issuable upon conversion of the Shares. 

 1.3    “Exchange Act” shall mean the U.S. Securities Exchange Act of
1934, as amended, or any similar U.S. federal statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 1.4    “Holder” shall mean the holders of Registrable Securities, securities convertible into Registrable Securities and any person holding such securities to whom the rights under
this Agreement have been transferred in accordance with Section 3.9 hereof. 
 1.5    “Registrable
Securities” means (i) the Conversion Stock, (ii) the shares of Common Stock issued or issuable to the Board of Regents of The University of Texas System, Akira Takashima and Mark E. Mummert pursuant to that certain Common Stock
Purchase Agreement dated May 15, 2001, (iii) the shares of Common Stock issued or issuable upon conversion of the Series B Preferred Stock issued upon exercise of the Warrants and (iv) any Common Stock of the Company issued or
issuable with respect to, or in exchange for or in replacement of the stock as described in clause (i), (ii) or (iii) or other securities convertible into or exercisable for Conversion Stock upon any stock split, stock dividend,
recapitalization, or similar event, provided, however, that shares of Common Stock or other securities shall only be treated as Registrable Securities if and so long as they have not been sold to or through a broker or dealer or
underwriter in a public distribution or a public securities transaction. 
 1.6    “Register,”
“Registered” and “Registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such
registration statement. 
 1.7    “Registration Expenses” shall mean all expenses incurred by the
Company in complying with Sections 3.1, 3.2 and 3.3 hereof, including, without limitation, all registration, qualification and filing fees, printing expenses, escrow fees, blue sky fees and expenses, fees and disbursements of counsel for the
Company and the expense of any special audits incident to or required by any such registration, provided, however, that Registration Expenses shall not include the Selling Expenses but shall include the compensation of regular
employees of the Company which shall be paid in any event by the Company. 
 1.8    “Restricted Securities” shall mean the securities of the Company required to bear the legend set forth in Section 2.2 hereof. 
 1.9    “Securities Act” shall mean the U.S. Securities Act of 1933, as amended, or any similar U.S. federal
statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 1.10    “Selling Expenses” shall mean all underwriting discounts, selling commissions, fees and disbursements of one counsel to the selling Holders and stock transfer taxes applicable to the
securities registered by the Holders. 
 1.11    “Shares” shall mean the shares of the Company’s
Series A Preferred Stock issued pursuant to the Series A Preferred Stock Purchase Agreement dated June 8, 2000, the shares of the Company’s Series A-1 Preferred Stock issued pursuant to the Series A-1 Preferred Stock Purchase Agreement
dated December 28, 2001, the shares of the Company’s Series A-1 Preferred 

  

 2 

 
Stock issued pursuant to the Series A-1 Preferred Stock Purchase Agreement dated November 20, 2002, the shares of the Company’s Series B Preferred
Stock issued pursuant to the Series B Preferred Stock Purchase Agreement dated April 30, 2004, the shares of the Company’s Series B Preferred Stock issued pursuant to the Stock Purchase Agreement dated July 31, 2005 between the
Company and Toray Industries, Inc., the shares of the Company’s Series C Preferred Stock issued pursuant to the Series C Preferred Stock Purchase Agreement dated December 16, 2005 (the “Series C Purchase Agreement”)
and the shares of the Company’s Series C Preferred Stock issued pursuant to the Toray Purchase Agreement. 
 1.12    “Warrants” shall mean the warrants to purchase shares of Series B Preferred Stock issued by the Company pursuant to the Note and Warrant Purchase Agreement dated October 31, 2003.

 2.    Restrictions on Transfer; Compliance with Securities Act; Market Standoff.

 2.1    Restrictions on Transfer.    The Shares and the Conversion Stock shall not
be sold, assigned, transferred or pledged except upon the conditions specified in this Section 2, which conditions are intended to ensure compliance with the provisions of the Securities Act. The Investors will cause any proposed purchaser,
assignee, transferee, or pledgee of the Shares or the Conversion Stock held by the Investors to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Section 2. 
 2.2    Restrictive Legend.    Each certificate representing (i) the Shares, (ii) the
Conversion Stock or (iii) any other securities issued in respect of the Shares or the Conversion Stock upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall (unless otherwise permitted by the
provisions of Section 2.3 below) be stamped or otherwise imprinted with a legend in the following form (in addition to any legend required under applicable state securities laws): 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY
REQUIREMENTS OF SAID ACT. COPIES OF THE AGREEMENT COVERING THE PURCHASE OF THESE SHARES AND RESTRICTING THEIR TRANSFER MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE
CORPORATION AT THE PRINCIPAL EXECUTIVE OFFICES OF THE CORPORATION. 
  

 3 

 The Investors and Holders consent to the Company making a notation on its records and giving instructions
to any transfer agent of the Shares or the Conversion Stock in order to implement the restrictions on transfer established in this Section 2. 
 2.3    Notice of Proposed Transfers.    The holder of each certificate representing Restricted Securities by acceptance thereof agrees to comply in all respects with the
provisions of this Section 2.3. Prior to any proposed sale, assignment, transfer or pledge of any Restricted Securities (other than (i) a transfer not involving a change in beneficial ownership, (ii) in transactions involving the
distribution without consideration of Restricted Securities by any Holder to any of its members, partners, or retired partners or members, or to the estate of any of its members, partners or retired partners or members, (iii) a transfer to an
affiliated fund, partnership or company, which is not a competitor of the Company, subject to compliance with applicable securities laws or (iv) transfers in compliance with Rule 144(k), so long as the Company is furnished with
satisfactory evidence of compliance with such Rule), unless there is in effect a registration statement under the Securities Act covering the proposed transfer, the holder thereof shall give written notice to the Company of such holder’s
intention to effect such transfer, sale, assignment or pledge. Each such notice shall describe the manner and circumstances of the proposed transfer, sale, assignment or pledge in sufficient detail, and, if requested by the Company, shall be
accompanied, at such holder’s expense, by either (i) a written opinion of legal counsel who shall be, and whose legal opinion shall be, reasonably satisfactory to the Company addressed to the Company, to the effect that the proposed
transfer of the Restricted Securities may be effected without registration under the Securities Act, or (ii) a “no action” letter from the Commission to the effect that the transfer of such securities without registration will not
result in a recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the holder of such Restricted Securities shall be entitled to transfer such Restricted Securities in accordance with the terms of the
notice delivered by the holder to the Company. Each certificate evidencing the Restricted Securities transferred as above provided shall bear the appropriate restrictive legend set forth in Section 2.2 above, except that such certificate shall
not bear such restrictive legend if in the opinion of counsel for such holder and in the reasonable opinion of the Company such legend is not required in order to establish compliance with any provision of the Securities Act. 
 2.4    Removal of Restrictions on Transfer of Securities.    Any legend referred to in Section 2.2
hereof stamped on a certificate evidencing the Restricted Securities and the stock transfer instructions and record notations with respect to such Restricted Security shall be removed and the Company shall issue a certificate without such legend to
the holder of such Restricted Security if such security is registered under the Securities Act, or if such holder provides the Company with an opinion of counsel (which may be counsel for the Company) reasonably acceptable to the Company to the
effect that a public sale or transfer of such security may be made without registration under the Securities Act or such holder provides the Company with reasonable assurances, which may, at the option of the Company, include an opinion of counsel
satisfactory to the Company, that such security can be sold pursuant to Rule 144(k) under the Securities Act. 
 2.5    Market Standoff Agreement.    Each Investor agrees, in connection with the Company’s initial public offering of the Company’s securities, not to sell, make any short sale of,
loan, grant any option for the purchase of, or otherwise dispose of any shares of capital stock of the Company, including, but not limited to, the Shares or the Conversion Stock (other than those 

  

 4 

 
included in the initial public offering registration, if applicable), without the prior written consent of the Company and the underwriters, for one hundred
eighty (180) days from the effective date of such initial public offering registration; provided, that every holder of at least five percent (5%) of the Company’s outstanding capital stock and the officers and directors of the Company
also agree to such restrictions. Each Investor further agrees that the Company may impose stop transfer instructions in order to enforce the foregoing covenant. 
 3.    Registration Rights. 
 3.1    Demand Registration. 
 (a)    If the Company shall receive at any time
after the earlier of (i) six (6) months after the effective date of the Company’s initial firm commitment underwritten public offering of its Common Stock under the Securities Act or (ii) April 30, 2008 a written request from the
Holders of at least a majority of the Registrable Securities then outstanding that the Company effect any registration, qualification or compliance with respect to at least forty percent (40%) of the Registrable Securities then outstanding, or
any lesser number of shares of Registrable Securities if the anticipated aggregate offering price exceeds $10,000,000, the Company will (i) within ten days of the receipt by the Company of such notice, give written notice of the proposed
registration, qualification or compliance to all other Holders and (ii) as soon as practicable, use reasonable efforts to effect such registration, qualification or compliance (including, without limitation, appropriate qualification under
applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act and any other governmental requirements or regulations) as may be so requested and as would permit or
facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are
specified in a written request received by the Company within 20 days after receipt of such written notice from the Company. Notwithstanding the foregoing, the Company shall not be obligated to take any action to effect any such registration,
qualification or compliance pursuant to this Section 3.1(a): 
 (i)    In any particular jurisdiction in which the
Company would be required to qualify as a foreign corporation, subject itself to taxation in that jurisdiction or execute a general consent to service of process in effecting such registration, qualification or compliance unless the Company is
already subject to service in such jurisdiction and except as may be required by the Securities Act; 
 (ii)    During
the period starting with the date sixty (60) days prior to the Company’s estimated date of filing of, and ending on the date six (6) months immediately following the effective date of, any registration statement pertaining to a public
offering of securities for the Company account, provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective; 
 (iii)    After the Company has effected one such registration pursuant to this Section 3.1(a), and such registrations have been
declared or ordered effective; 
  

 5 

 (iv)    If the Company is entitled to use a registration statement on Form S-3
(or any successor form to Form S-3) or any similar short-form registration statement to register shares in a public offering of securities; or 
 (v)    If the Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company
or its stockholders for a registration statement to be filed in the near future, then the Company’s obligation to register, qualify or comply under this Section 3.1(a) shall be deferred for a period not to exceed one hundred twenty
(120) days from the date of receipt of written request from the Holders; provided, however, that the Company shall not exercise such right more than once in any twelve-month period. 
 Subject to the foregoing clauses (i) through (v), the Company shall file a registration statement covering the Registrable Securities so requested
to be registered as soon as practicable, after receipt of the request or requests of the Holders. 
 (b)    Underwriting.    In the event that the stockholders initiating a registration pursuant to Section 3.1(a) intend to distribute Registrable Securities by means of an underwriting,
they shall so advise the Company in their request and the Company shall so advise the Holders as part of the notice given pursuant to Section 3.1(a). In such event, the right of any Holder to registration pursuant to Section 3.1(a) shall
be conditioned upon such Holder’s participation in the underwriting arrangements required by this Section 3.1, and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent requested shall be limited to
the extent provided herein. 
 The Company shall (together with all Holders proposing to distribute their securities through such
underwriting) enter into an underwriting agreement in customary form with the managing underwriter of recognized national standing selected for such underwriting by the Company and reasonably acceptable to a majority of the Holders proposing to
distribute their securities through such underwriting. Notwithstanding any other provision of this Section 3.1, if the managing underwriter determines that marketing factors require a limitation of the number of shares to be underwritten, the
managing underwriter may limit the Registrable Securities and other securities to be distributed through such underwriting. The Company shall so advise all Holders distributing their securities through such underwriting of such limitation and the
number of shares of Registrable Securities that may be included in the registration (and underwriting if any) shall be allocated among all Holders in proportion, as nearly as practicable, to the respective amounts of Registrable Securities requested
by such Holders to be included in such Registration Statement. No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. To facilitate the allocation of
shares in accordance with the above provisions, the Company may round the number of shares allocated to any Holder or Holders to the nearest 100 shares. In no event shall the number of Registrable Securities underwritten in an offering be limited
unless and until all shares held by persons other than the holders of the Registrable Securities are completely excluded from such offering. 
 If any Holder of Registrable Securities disapproves of the terms of the underwriting, such Holder may elect to withdraw therefrom by written notice to the Company, the managing 

  

 6 

 
underwriter and the Holders. The Registrable Securities and/or other securities so withdrawn shall also be withdrawn from registration, and such Registrable
Securities shall not be transferred in a public distribution prior to one hundred eighty (180) days after the effective date of such registration, or such other shorter period of time as the underwriters may require. The Company may impose stop
transfer instructions with its transfer agent in order to enforce the foregoing covenant. 
 3.2    Company Registration.
 (a)    Notice of
Registration.    If at any time or from time to time the Company shall determine to register any of its securities, either for its own account or the account of a security holder or holders, other than (i) a registration
relating solely to employee benefit plans, (ii) a registration relating solely to a Rule 145 transaction, or (iii) a registration pursuant to Section 3.1 hereof, the Company will promptly give to each Holder written notice
thereof and include in such registration (and any related qualification under blue sky laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests, made within 20
days after receipt of such written notice from the Company, by any Holder. 
 (b)    Underwriting.    If the registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the Holders as a part of
the written notice given pursuant to Section 3.2(a). In such event the right of any Holder to registration pursuant to Section 3.2 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of
Registrable Securities in the underwriting to the extent provided herein. 
 All Holders proposing to distribute their securities through
such underwriting shall (together with the Company) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by the Company. Notwithstanding any other provision of this Section 3.2, if
the managing underwriter determines that marketing factors require a limitation of the number of shares to be underwritten, the managing underwriter may limit the Registrable Securities and other securities to be distributed through such
underwriting; provided, however, that except in connection with the Company’s initial underwritten public offering of Common Stock where Registrable Securities may be entirely excluded, the number of Registrable Securities shall
not be limited to less than ten percent (10%) of the aggregate number of shares proposed to be included in such underwriting. The Company shall so advise all Holders distributing their securities through such underwriting of such limitation and
the number of shares of Registrable Securities that may be included in the registration (and underwriting if any) shall be allocated among all Holders in proportion, as nearly as practicable, to the respective amounts of Registrable Securities
requested by such Holders to be included in such Registration Statement. No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. To facilitate the
allocation of shares in accordance with the above provisions, the Company may round the number of shares allocated to any Holder or Holders to the nearest 100 shares. In no event shall the number of Registrable Securities underwritten in an offering
be limited unless and until all shares held by persons other than the holders of the Registrable Securities and the Company are completely excluded from such offering. 
  

 7 

 If any Holder or Holders disapprove of the terms of any such underwriting, such Holder or Holders may
elect to withdraw therefrom by written notice to the Company and the managing underwriter. Any securities excluded or withdrawn from such underwriting shall be withdrawn from such registration, and shall not be transferred in a public distribution
prior to one hundred eighty (180) days after the effective date of the registration statement relating thereto, or such other shorter period of time as the underwriters may require. The Company may impose stop transfer instructions with its
transfer agent in order to enforce the foregoing covenant. 
 (c)    Right to Terminate
Registration.    The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 3.2 prior to the effectiveness of such registration whether or not any Holder has elected to
include securities in such registration. The Registration Expenses of such withdrawn registration shall be borne by the Company in accordance with Section 3.4 hereof. 
 3.3    Registration on Form S-3.
 (a)    If any Holder or Holders request in writing that the Company file a registration statement on Form S-3 (or any successor form to Form S-3), or any similar short-form registration
statement, for a public offering of Registrable Securities, the reasonably anticipated aggregate price to the public of which, net of underwriting discounts and commissions (if any), would exceed $1,000,000 and the Company is a registrant entitled
to use Form S-3 to register the Registrable Securities for such an offering, the Company shall use reasonable efforts to cause such Registrable Securities to be registered on such form for the offering and to cause such Registrable Securities
to be qualified in such jurisdictions as the Holder or Holders may reasonably request; provided, however, that the Company shall not be required to effect more than two (2) such registration in any twelve (12) month period.
The provisions of Section 3.1(b) shall be applicable to each registration initiated under this Section 3.3. 
 (b)    Notwithstanding the foregoing, the Company shall not be obligated to take any action pursuant to this Section 3.3: (i) in any particular jurisdiction in which the Company would be required to execute a
general consent to service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; (ii) if the Company,
within ten (10) days of the receipt of the request of the initiating Holders, gives notice of its bona fide intention to effect the filing of a registration statement with the Commission within ninety (90) days of receipt of such request
(other than with respect to a registration statement relating to a Rule 145 transaction, or an offering solely to employees); (iii) during the period starting with the date sixty (60) days prior to the Company’s estimated date of
filing of, and ending on the date six (6) months immediately following, the effective date of any registration statement pertaining to a public offering of securities for the Company’s account, provided that the Company is actively
employing in good faith all reasonable efforts to cause such registration statement to become effective; (iv) if the Company shall furnish to such Holder a certificate signed by the President of the Company stating that in the good faith
judgment of the Board of Directors it would be seriously detrimental to the Company or its stockholders for registration statements to be filed in the near future, then the Company’s obligation to file a registration statement shall be deferred
for a period not to exceed one hundred twenty (120)

  

 8 

 
days from the receipt of the request to file such registration by such Holder; provided, however, that the Company shall not exercise such
right more than once in any twelve-month period. 
 3.4    Expenses of Registration.    All Registration Expenses incurred in connection with registrations pursuant to Sections 3.1, 3.2 and 3.3 shall be borne by the Company. All
Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the holders of securities included in such registration pro rata among each other on the basis of the number of shares so registered; provided,
however, that the Company shall not be required to pay for the Registration Expenses of any registration proceeding begun pursuant to Sections 3.1 or 3.3 if the registration request is subsequently withdrawn at the request of the Holders
holding a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses), unless the Holders holding a majority of the Registrable Securities agree to forfeit their right to a demand
registration pursuant to Section 3.1; provided further, however, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the financial condition, business, or prospects of the Company from
that known to the Holders at the time of their request, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 3.1. 
 3.5    Registration Procedures.    In the case of each registration, qualification or compliance
effected by the Company pursuant to this Section 3, the Company will keep each Holder advised in writing as to the initiation of each registration, qualification and compliance and as to the completion thereof. Subject to Section 3.4, the
Company, at its expense, will: 
 (a)    Prepare and file with the Commission a registration statement with respect to
such securities and use reasonable efforts to cause such registration statement to become and remain effective for thirty (30) days or less if the distribution described in the Registration Statement has been completed; 
 (b)    Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used
in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement. 
 (c)    Furnish to the Holders participating in such registration and to the underwriters of the securities being registered such
reasonable number of copies of the registration statement, preliminary prospectus, final prospectus and such other documents as such underwriters may reasonably request in order to facilitate the public offering of such securities. 
 (d)    Use reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions. 
 (e)    In the event of any underwritten public
offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the 

  

 9 

 
managing underwriter(s) of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an
agreement. 
 (f)    Notify each Holder of Registrable Securities covered by such registration statement at any time
when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a
material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 
 3.6    Indemnification.
 (a) The Company will indemnify each Holder, each of its officers, directors and partners, and each person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification
or compliance has been effected pursuant to this Section 3, and each underwriter, if any, and each person who controls any underwriter within the meaning of Section 15 of the Securities Act, against all expenses, claims, losses, damages or
liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained
in any registration statement, prospectus, offering circular or other document, or any amendment or supplement thereto, incident to any such registration, qualification or compliance, or based on any omission (or alleged omission) to state therein a
material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, or any violation by the Company of the Securities Act or the Exchange Act applicable to
the Company in connection with any such registration, qualification or compliance, and the Company will reimburse each such Holder, each of its officers, directors, partners and each person controlling such Holder, each such underwriter and each
person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating, preparing or defending any such claim, loss, damage, liability or action, provided that the Company will not be
liable in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with written
information furnished to the Company by an instrument duly executed by such Holder, controlling person or underwriter specifically for use therein, or the failure of such Holder to deliver a Prospectus that was delivered to the Holder prior to a
sale or sales by such Holder. 
 (b) Each Holder will, if Registrable Securities held by such Holder are included in the securities as to
which such registration, qualification or compliance is being effected, indemnify the Company, each of its directors and officers, each underwriter, if any, of the Company’s securities covered by such a registration statement, each person who
controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, and each other Holder, each of its officers, directors, partners and each person controlling such Holder within the meaning of Section 15 of
the Securities Act, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement,
prospectus, offering 

  

 10 

 
circular or other document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, and will reimburse the Company, such Holders, such directors, officers, persons, underwriters or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending
any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus,
offering circular or other document in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by the indemnifying Holder specifically for use therein, or the failure of such Holder to deliver
a Prospectus that was delivered to the Holder prior to a sale or sales by such Holder. Notwithstanding the foregoing, the liability of each Holder under this subsection (b) shall be limited to the proportion of any such loss, claim, damage,
liability or expense which is equal to the proportion that the public offering price of the shares sold by the Holder under such registration statement bears to the total public offering price of all securities sold thereunder, but not to exceed the
proceeds received by such Holder from the sale of Registrable Securities covered by such registration statement unless such liability resulted from willful misconduct by such Holder. 
 (c)    Each party entitled to indemnification under this Section 3.6 (the “Indemnified Party”) shall give
notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party
to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval
shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such party’s expense, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Section 3 unless the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend such action and provided further, that the Indemnifying Party shall
not assume the defense for matters as to which there is a conflict of interest or separate and different defenses but shall bear the expense of such defense nevertheless. No Indemnifying Party, in the defense of any such claim or litigation, shall,
except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release
from all liability in respect to such claim or litigation. 
 (d)    If the indemnification provided for
paragraphs (a) through (c) of this Section 3.6 is unavailable or insufficient to hold harmless an Indemnified Party under such paragraphs in respect of any losses, claims, damages or liabilities or actions in respect thereof referred
to therein, then each Indemnifying Party shall in lieu of Indemnifying such Indemnified Party contribute to the amount paid or payable by such Indemnified Party as a result of such losses, claims, damages, liabilities or actions in such proportion
as appropriate to reflect the relative fault of the Company, on the one hand, and the underwriters and the Holder of such Registrable Securities, on the other, in connection with the statements or omissions which resulted in such losses, claims,
damages, liabilities or actions as well as any other relevant equitable considerations, including the failure to give any notice under Section 3.6(c). The relative fault shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact relates to 

  

 11 

 
information supplied by the Company, on the one hand, or the underwriters or the Holders of such Registrable Securities, on the other, and to the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and each of the Holders agrees that it would not be just and equitable if contributions pursuant to this
paragraph were determined by pro rata allocation (even if all of the Holders of such Registrable Securities were treated as one entity for such purpose) or by any other method of allocation which did not take account of the equitable considerations
referred to above in this paragraph. The amount paid or payable by an Indemnified Party as a result of the losses, claims, damages, liabilities or action in respect thereof, referred to above in this paragraph, shall be deemed to include any legal
or other expenses reasonably incurred by such Indemnified Party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this paragraph, no Holder shall be required to contribute any amount in excess
of the lesser of (i) the proportion that the public offering price of shares sold by such Holder under such registration statement bears to the total public offering price of all securities sold thereunder, but not to exceed the proceeds
received by such Holder for the sale of Registrable Securities covered by such registration statement and (ii) the amount of any damages which they would have otherwise been required to pay by reason of such untrue or alleged untrue statement
or omission. No person guilty of fraudulent misrepresentations (within the meaning of Section 11(f) of the Securities Act), shall be entitled to contribution from any person who is not guilty of such fraudulent misrepresentation. 
 3.7    Information by Holder.    The Holder or Holders of Registrable Securities included in any
registration shall furnish to the Company such information regarding such Holder or Holders, the Registrable Securities held by them and the distribution proposed by such Holder or Holders as the Company may reasonably request in writing and as
shall be required in connection with any registration, qualification or compliance referred to in this Section 3. 
 3.8    Rule 144 Reporting.    With a view to making available the benefits of certain rules and regulations of the Commission which may at any time permit the sale of the Restricted
Securities to the public without registration, after such time as a public market exists for the Common Stock of the Company, the Company agrees to use reasonable efforts to: 
 (a)    Make and keep public information available, as those terms are understood and defined in Rule 144 under the Securities
Act, at all times after the effective date that the Company becomes subject to the reporting requirements of the Securities Act or the Exchange Act. 
 (b)    Use reasonable efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after
it has become subject to such reporting requirements); 
 (c)    So long as a Holder owns any Restricted Securities to
furnish to the Holder forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 (at any time after 90 days after the effective date of the first registration statement filed
by the Company for an offering of its securities to the general public), and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of
the Company, and 

  

 12 

 
such other reports and documents of the Company and other information in the possession of or reasonably obtainable by the Company as a Holder may reasonably
request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration. 
 3.9    Transfer of Registration Rights.    The rights to cause the Company to register securities granted Holders under Sections 3.1, 3.2 and 3.3 may be assigned to a
transferee or assignee in connection with any transfer or assignment of Registrable Securities by a Holder of not less than 100,000 shares (as adjusted for stock splits, stock dividends, recapitalizations and similar events) of Registrable
Securities (or a lesser number if such number represents 100% of the Holders’ Registrable Securities) or to any transferee or assignee who is a partner or member (or retired partner or member) of a Holder or the estate of such partner or member
(or retired partner or member), provided that such transfer may otherwise be effected in accordance with applicable securities laws. 
 3.10    Termination of Registration Rights.    The rights granted under this Section 3 shall terminate on the earlier to occur of the following: (i) on the third anniversary of the
consummation of the initial underwritten public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act; or (ii) as to a particular Holder, when such Holder is eligible to sell all of its
Registrable Securities within any 90 day period in reliance on Rule 144 under the Securities Act. 
 3.11    Limitations on Subsequent Registration Rights.    The Company shall not, without the prior written consent of the Holders of at least fifty percent (50%) of the Registrable
Securities, enter into any agreement (other than this Agreement) with any holder or prospective holder of any securities of the Company which would allow such holder or prospective holder (a) to include securities of the Company in any
Registration Statement upon terms which are the same or more favorable to such holder or prospective holder than the terms on which holders of Registrable Securities may include shares in such registration or (b) to make a demand registration
which could result in such registration statement being declared effective prior to the dates set forth in Section 3.1. 
 4.    Investors’ Right of First Refusal.
 4.1    Right of First
Refusal.    The Company hereby grants to each Investor holding at least 100,000 shares of Conversion Stock, on the terms set forth in this Section 4, the right of first refusal to purchase up to fifty percent
(50%) of such Investor’s pro rata share of the New Securities (as defined in Section 4.2) which the Company may, from time to time, propose to sell and issue. The Investors may purchase said New Securities on the same terms and at the
same price at which the Company proposes to sell the New Securities. For the purposes of this right of first refusal, an Investor’s pro rata share of the New Securities is a fraction, the numerator of which is the total number of shares of
Common Stock held by such Investor (including any shares of Common Stock issuable upon conversion of Preferred Stock held by such Investor) and the denominator of which is the total number of shares of the Company’s Common Stock outstanding
(including any shares of Common Stock issuable upon conversion of or exercise of, as the case may be, Preferred Stock, options, warrants or other convertible securities) immediately prior to the issuance of the New Securities. 
  

 13 

 4.2    New Securities.    “New
Securities” shall mean any capital stock of the Company, whether now authorized or not, and any rights, options or warrants to purchase said capital stock, and securities of any type whatsoever that are, or may become, convertible into said
capital stock; provided that New Securities does not include (i) the Shares, the Conversion Stock or the securities issuable upon exercise of the Warrants, (ii) securities offered pursuant to a registration statement filed under the
Securities Act, (iii) securities issued pursuant to the acquisition of another corporation by the Company by merger, purchase of substantially all of the assets or other reorganization, (iv) securities issued or issuable to officers,
directors, employees, advisors, consultants or service providers of the Company pursuant to any plan or arrangement approved by the Board of Directors of the Company, (v) securities issued pursuant to agreements to license technology and/or
provide sponsored research approved by the Board of Directors of the Company and (vi) securities issued in connection with equipment leasing or equipment financing arrangements approved by the Board of Directors of the Company. 
 4.3    Notice of Proposed Issuance.    In the event the Company proposes to undertake an issuance of New
Securities, it shall give to the Investors written notice (the “Notice”) of its intention, describing the type of New Securities, the price, the terms upon which the Company proposes to issue the same, the date of the proposed
issuance and a statement as to the number of days from receipt of such Notice within which the Investors must respond to such Notice. The Investors shall have fifteen (15) days from the date of receipt of the Notice to purchase any or all of
the New Securities for the price and upon the terms specified in the Notice by giving written notice to the Company and stating therein the quantity of New Securities to be purchased and forwarding payment for such New Securities to the Company if
immediate payment is required by such terms, or in any event no later than the date of the proposed issuance as set forth in the Notice. 
 4.4    Transfer of Rights.    The right of first refusal granted under this Section 4 may not be assigned or transferred, except that such right is assignable or transferable by each
Investor to any transferee or assignee (i) who is a partner or member (or retired partner or member) of an Investor or the estate of such partner or member (or retired partner or member) or (ii) that is a wholly owned subsidiary or parent
of, or to any corporation or entity that is, within the meaning of the Securities Act, controlling, controlled by or under common control with, any such Investor; provided, however, that the provisions of this Section 4 shall be
binding upon any such assignee or transferee. 
 4.5    Termination of Rights.    The right of
first refusal granted under this Section 4 shall expire upon: (i) the closing of the Company’s initial underwritten public offering pursuant to an effective registration statement filed by the Company under the Securities Act; or
(ii) for each Investor, the date on which such Investor first fails to exercise in full its right to purchase New Securities or no longer holds a minimum of 100,000 shares of Conversion Stock. 
 4.6    Existing Investor Waiver.    Each Existing Investor hereby (i) consents to the Company issuing
shares of its Series C Preferred Stock pursuant to the Series C Purchase Agreement and the Toray Purchase Agreement, (ii) waives any and all rights of first refusal such Existing Investor has under Section 4 of the Prior
Agreement to purchase any portion of the Company’s Series C Preferred Stock described in clause (i) above, including any of the Company’s Common Stock issued upon conversion thereof and (iii) waives any and all rights to
receive notice of the 

  

 14 

 
Company’s intention to issue shares of its Series C Preferred Stock described in clause (i) above. The waiver set forth in this subsection
shall become effective and binding on all Existing Investors upon the execution of this Agreement by the Company and by Existing Investors holding at least a majority of the Company’s Registrable Securities (as defined in the Prior Agreement).

 5.    Affirmative Covenants.    The Company hereby covenants and agrees as follows:

 5.1    Financial Information.    The Company will provide to each Investor who continues to
hold at least 100,000 shares of Conversion Stock (subject to appropriate adjustment for stock splits, stock dividends, combinations and other recapitalizations) with reports set forth below. 
 (a)    As soon as practicable after the end of each fiscal year, and in any event within one hundred twenty (120) days
thereafter, consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of such fiscal year, and consolidated statements of income and consolidated statements of changes in financial position of the Company and its
subsidiaries, if any, for such year, prepared in accordance with generally accepted accounting principles and setting forth in each case in comparative form the figures for the previous fiscal year (or, at the election of the Company, setting forth
in comparative form the budgeted figures for the fiscal year then reported). 
 (b)    As soon as practicable after the
end of each quarter, and in any event within sixty (60) days after each quarterly accounting period, an unaudited quarterly report including a balance sheet, profit and loss statement and cash flow analysis (prepared in accordance with
generally accepted accounting principles other than for accompanying notes and subject to changes resulting from year-end adjustments). 
 The rights granted pursuant to Section 5.1 may not be assigned or otherwise conveyed by any Investor or by any subsequent transferee of any such rights without the prior written consent of the Company. 
 5.2    Inspection Rights.
 (a)    On an annual basis during the week in which the Company holds its annual stockholders meeting, the Company shall permit each Investor who continues to hold at least 100,000 shares of
Conversion Stock (subject to appropriate adjustment for stock splits, stock dividends, combinations and other recapitalizations), at such Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account
and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Investor. 
 (b)    Anything in Section 5.2 to the contrary notwithstanding, no Investor or transferee of an Investor by reason of this Agreement shall have access to any trade secrets or classified
information of the Company. Each Investor hereby agrees to hold in confidence and trust and not to misuse or disclose any confidential information provided pursuant to this Section 5.2 and any transferee of an Investor must agree, in writing,
to the same. The Company shall not be required to comply with this Section 5.2 in respect of any Investor or transferee of an Investor whom the Company reasonably determines to be a competitor or an officer, employee, director or greater than

  

 15 

 
5% stockholder of a competitor or to the extent compliance would result in disclosure of trade secrets. 
 5.3    Termination of Covenants.    The covenants set forth in this Section 5 shall terminate and be
of no further force or effect upon the closing of the Company’s initial underwritten public offering pursuant to an effective registration statement filed by the Company under the Securities Act. 
 6.    Miscellaneous. 
 6.1    Waivers and Amendments.    With the written consent of the Company and the record holders of more than fifty percent (50%) of the Registrable Securities then outstanding, the
obligations of the Company and the rights of the Holders and Investors may be waived (either generally or in a particular instance, either retroactively or prospectively and either for a specified period of time or indefinitely), and with the same
consent the Company, when authorized by resolution of its Board of Directors, may enter into a supplementary agreement for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Agreement;
provided, however, that no such waiver or supplemental agreement shall reduce the aforesaid percentage of the Registrable Securities, the holders of which are required to consent to any waiver or supplemental agreement without the consent of the
record holders of all of the Registrable Securities. In the event of a subsequent closing with an investor as provided for in Section 2.3 of the Series C Purchase Agreement, such investor shall become a party to this Agreement as an
“Investor” upon the Company’s receipt from such investor of an executed counterpart signature page to this Agreement. 
 Neither this Agreement nor any provisions hereof may be changed, waived, discharged or terminated orally, but only by a signed statement in writing. 
 6.2    Governing Law.    This Agreement shall be governed in all respects by the laws of the State of Delaware as such laws are applied to agreements entered into among
Delaware residents to be performed entirely within Delaware, without regard to conflict of laws rules. 
 6.3    Successors and Assigns.    Except as otherwise expressly provided herein, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns,
heirs, executors and administrators of the parties hereto. 
 6.4    Entire Agreement.    This
Agreement constitutes the full and entire understanding and agreement between the parties with regard to the subject matter hereof. 
 6.5    Notices.    All notices and other communications required or permitted under this Agreement shall be in writing and shall be delivered personally by hand or by courier, mailed by United
States first-class mail, postage prepaid, sent by facsimile or sent by electronic mail directed (a) if to an Investor, at such Investor’s address, facsimile number or electronic mail on the Company’s records, or at such other address,
facsimile number or electronic mail address as such Investor may designate by ten (10) days’ advance written notice to the Company or (b) if to the Company, to its address, facsimile number or electronic mail address set forth on its
signature page to this Agreement and directed to the attention of the President, or at such other address, facsimile 
  

 16 

 
number or electronic mail address as the Company may designate by ten (10) days’ advance written notice to each Investor. All such notices and
other communications shall be effective or deemed given upon personal delivery, on the date of mailing, upon confirmation of facsimile transfer or upon confirmation of electronic mail delivery. Notwithstanding the foregoing, all notices and
communications to addresses outside the United States shall be given by facsimile or by overnight or two-day courier service and shall be effective or deemed given upon confirmation of facsimile transfer or upon personal delivery. With respect to
any notice given by the Company under any provision of the Delaware General Corporation Law or the Company’s charter or bylaws, each Investor agrees that such notice may given by facsimile or by electronic mail. 
 6.6    Titles and Subtitles.    The titles of the paragraphs and subparagraphs of this Agreement are for
convenience of reference only and are not to be considered in construing this Agreement. 
 6.7    Stock Splits,
etc.    Appropriate adjustments shall be made in the number and class of shares in the event of a stock dividend, stock split, reverse stock split, combination, reclassification or like change in the capital structure of the
Company. 
 6.8    Termination of Prior Agreement.    Pursuant to Section 6.1 of the
Prior Agreement, the record holders of more than 50% of the Registrable Securities (as that term is defined in the Prior Agreement) then outstanding hereby terminate the Prior Agreement on behalf of all Holders and Investors (as those terms are
defined in the Prior Agreement) and replace the Prior Agreement on behalf of all Holders and Investors (as those terms are defined in the Prior Agreement) with this Agreement, and any Holder or Investor (as those terms are defined in the Prior
Agreement) who does not sign this Agreement shall be bound by the terms and conditions of this Agreement pursuant to Section 6.1 of the Prior Agreement as if that Holder or Investor (as those terms are defined in the Prior Agreement) had signed
this Agreement. 
 6.9    Counterparts.    This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together shall constitute one instrument. 
  

 17 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set forth
above. 
  

			
	 “COMPANY”
  
 ACOLOGIX, INC.

		
	By:	 	/S/    JOHN J. BUCKLEY        
		
	Name:	 	John J. Buckley
		
	Title:	 	Chief Financial Officer
		
	 Address:
	 	
	
	 3960 Point Eden Way

	 Hayward, CA 94545

	 Facsimile: 510.786.1116

			
	 “INVESTOR”
  
 NOMURA R&A II VENTURE CAPITAL FUND LIMITED PARTNERSHIP

		
	By:	 	/S/    AKIHITO WATANABE        
		 	 Akihito Watanabe
 President

			
	 “INVESTOR”
  
 JAPAN ASIA INVESTMENT CO., LTD.

		
	By:	 	/S/    TOYOJI TATSUOKA        
		 	 Toyoji Tatsuoka
 President & CEO

			
	 “INVESTOR”
  
 JAIC AMERICA, INC.

		
	By:	 	/S/    YASUHISA UMEZU        
		 	 Yasuhisa (Jack) Umezu
 President & COO

	
	JAIC USSII NO. 1, LLC
		
	By:	 	/S/    YASUHISA UMEZU        
		 	 Yasuhisa (Jack) Umezu
 Asset Manager

			
	 “INVESTOR”
  
 EAST GATE PRIVATE EQUITY FUND III, L.P.

		
	By:	 	/S/    KEN CHOI        
		 	 Ken Choi
 Managing Director

			
	 “INVESTOR”
  
 FUJI GREEN CO., LTD.

		
	By:	 	 /s/    [authorized
signature]        

		
	Name:	 	  
		
	Title:	 	  

			
	 “INVESTOR”
  
 KYOKUTO SECURITIES CO., LTD.

		
	By:	 	/S/    HIROYUKI KIKUCHI        
		 	 Hiroyuki Kikuchi
 President and Chief Executive Officer

			
	 “INVESTOR”
  
 MIZUHO SECURITIES CO., LTD.

		
	By:	 	/S/    YASUHIKO SATO        
		 	 Yasuhiko Sato
 General Manager

			
	 “INVESTOR”
  
 SHIN NIHON JITSUGYO CO., LTD.

		
	By:	 	/S/    HIROSHI KONISHI        
		 	 Hiroshi Konishi
 President & CEO

			
	 “INVESTOR”
  
 HIROSHI KONISHI

		
	By:	 	/S/    HIROSHI KONISHI        
		 	 Hiroshi Konishi

			
	 “INVESTOR”
  
 BIO-SIGHT INCUBATE 1ST. INVESTMENT LIMITED PARTNERSHIP

		
	By:	 	/S/    MASAYUKI TANI        
		 	 Masayuki Tani
 President

			
	 “INVESTOR”
  
 NISSAY CAPITAL NO. 2 INVESTMENT PARTNERSHIP

		
	By:	 	/S/    YUSUKE SASAKI        
		 	 Yusuke Sasaki
 President

			
	 “INVESTOR”
  
 MILLENNIA 2000 VENTURE CAPITAL INVESTMENT LIMITED PARTNERSHIP

		
	By:	 	/S/    TATSUYA
KUROYANAGI        
		 	 Tatsuya Kuroyanagi
 Executive Officer & Chairman
 Millennia Venture Partners Co., Ltd.
 General Partner of Millennia 2000 Venture Capital
 Investment Limited Partnership

			
	 “INVESTOR”
  
 TOKIO MARINE AND NICHIDO FIRE INSURANCE CO., LTD.

		
	By:	 	/S/    TAKASHI YOSHIKAWA        
		 	 Takashi Yoshikawa
 General Manager, New Financial Markets

			
	 “INVESTOR”
  
 AOZORA INVESTMENT I VENTURE CAPITAL LIMITED PARTNERSHIP

		
	By:	 	/S/    KAZUNARI
TAKANOHASHI        
		 	 Kazunari Takanohashi 
 President

	
	AOZORA INVESTMENT II VENTURE CAPITAL LIMITED PARTNERSHIP
		
	By:	 	/S/    KAZUNARI
TAKANOHASHI        
		 	 Kazunari Takanohashi 
 President

			
	 “INVESTOR”
  
 RESONA CAPITAL CO., LTD.

		
	By:	 	/S/    HIROHIDE
TAKAHASHI        
		 	 Hirohide Takahashi 
 President

			
	 “INVESTOR”
  
 ITX INTERNATIONAL EQUITY CORPORATION

		
	By:	 	/S/     TAKEHITO JIMBO        
		 	 Takehito Jimbo
 President / CEO

			
	 “INVESTOR”
  
 CSK-VC LIFE SCIENCE INVESTMENT FUND

		
	By:	 	/S/    SHUNICHI ISHIMURA        
		 	 Shunichi Ishimura
 President & CEO
 CSK Venture Capital Co., Ltd.

			
	 “INVESTOR”
  
 MITSUBISHI UFJ CAPITAL CO., LTD.

		
	By:	 	/S/    KAZUHIKO TOKITA        
		 	 Kazuhiko Tokita
 President

			
	 “INVESTOR”
  
 LIFE SCIENCE VENTURE FUND

		
	By:	 	/S/    TADASHI MATSUMOTO        
		 	 Tadashi Matsumoto, Ph.D.
 President and CEO,
 ReqMed Company, Ltd.
 as General Partner of LSVF

			
	 “INVESTOR”
  
 ORIX FUND NO. 4

		
	By:	 	/S/    AKIRA HIROSE        
		 	 Akira Hirose
 President
 ORIX Capital Corporation
 General Partner of ORIX Fund
No. 4

			
	
	ORIX FUND NO. 7
		
	By:	 	/S/    AKIRA HIROSE        
		 	 Akira Hirose
 President
 ORIX Capital Corporation
 General Partner of ORIX Fund
No. 7

	
	ORIX FUND NO. 8
		
	By:	 	/S/    AKIRA HIROSE        
		 	 Akira Hirose
 President
 ORIX Capital Corporation
 General Partner of ORIX Fund
No. 8

	
	ORIX FUND NO. 9
		
	By:	 	/S/    AKIRA HIROSE        
		 	 Akira Hirose
 President
 ORIX Capital Corporation
 General Partner of ORIX Fund
No. 9

			
	 “INVESTOR”
  
 AQUA RIMCO BIOTECHNOLOGY NO. 1 INVESTMENT PARTNERSHIP

		
	By:	 	/S/    YOSHIHIKO
TAKAMIYA        
		 	 Yoshihiko Takamiya
 President
 Aqua Research Investment Management Co., Ltd.

	
	AQUARIMCO NO. 4 INVESTMENT ENTERPRISE PARTNERSHIP FUND
		
	By:	 	/S/    YOSHIHIKO
TAKAMIYA        
		 	 Yoshihiko Takamiya
 President
 Aqua Research Investment Management Co., Ltd.

	
	AQUARIMCO NO. 8 INVESTMENT ENTERPRISE PARTNERSHIP FUND
		
	By:	 	/S/    YOSHIHIKO TAKAMIYA
        
		 	 Yoshihiko Takamiya
 President
 Aqua Research Investment Management Co., Ltd.

	
	AQUARIMCO NO. 10 INVESTMENT ENTERPRISE PARTNERSHIP FUND
		
	By:	 	/S/    YOSHIHIKO
TAKAMIYA        
		 	 Yoshihiko Takamiya
 President
 Aqua Research Investment Management Co., Ltd.

	
	CJA PAN-PACIFIC RAINBOW NO. 1 INVESTMENT PARTNERSHIP
		
	By:	 	/S/    YOSHIHIKO
TAKAMIYA        
		 	 Yoshihiko Takamiya
 President
 Aqua Research Investment Management Co., Ltd.

			
	 “INVESTOR”
  
 WILLIAM F. BENNETT, PH.D.

		
	By:	 	/S/    WILLIAM F.
BENNETT        
		 	William F. Bennett, Ph.D.

			
	 “INVESTOR”
  
 ASAHI LIFE CAPITAL NO. 3 INVESTMENT ENTERPRISE PARTNERSHIP

		
	By:	 	/S/    SADAO SUZUKI        
		
	 Name:
	 	Sadao Suzuki
		
	Title:	 	President, Asahi Life Capital Co., Ltd.

			
	 “INVESTOR”
  
 GRANDE VAGUE, LIMITED

		
	By:	 	/S/    MASAYO EBIHARA        
		 	 Masayo Ebihara
 President

			
	 “INVESTOR”
  
 TORAY INDUSTRIES, INC.

		
	By:	 	/S/    NOBORU MINOWA        
		
	Name:	 	Noboru Minowa
		
	Title:	 	 General Manager

			
	 “INVESTOR”
  
 NIF SMBC VENTURES CO., LTD.

		
	By:	 	/S/    SHIN-ICHI
YAMAMURA        
		 	 Shin-ichi Yamamura, President

			
	
	VENTURE CAPITAL INVESTMENT LIMITED PARTNERSHIP NIF GLOBAL FUND
		
	By:	 	/S/    SHIN-ICHI
YAMAMURA        
		 	 Shin-ichi Yamamura, President,
 NIF SMBC Ventures Co., Ltd.,
 General Partner of Venture Capital Investment Limited Partnership NIF Global Fund

	
	 NIF JAPAN CAPITAL GROWTH FUND
 2005H-1 INVESTMENT LIMITED PARTNERSHIP

		
	By:	 	/S/    SHIN-ICHI
YAMAMURA        
		 	 Shin-ichi Yamamura, President,
 NIF SMBC Ventures Co., Ltd.,
 General Partner of NIF Japan Capital Growth Fund 2005H-1 Investment Limited Partnership

	
	 NIF JAPAN CAPITAL GROWTH FUND
 2005H-2 INVESTMENT LIMITED PARTNERSHIP

		
	By:	 	/S/    SHIN-ICHI
YAMAMURA        
		 	 Shin-ichi Yamamura, President,
 NIF SMBC Ventures Co., Ltd.,
 General Partner of NIF Japan Capital Growth Fund 2005H-2 Investment Limited Partnership

	
	 NIF JAPAN CAPITAL GROWTH FUND
 2005H-3 INVESTMENT LIMITED PARTNERSHIP

		
	By:	 	/S/    SHIN-ICHI
YAMAMURA        
		 	 Shin-ichi Yamamura, President,
 NIF SMBC Ventures Co., Ltd.,
 General Partner of NIF Japan Capital Growth Fund 2005H-3 Investment Limited Partnership

			
	 “INVESTOR”
  
 SMBC CAPITAL NO. 6 VENTURE CAPITAL INVESTMENT LIMITED PARTNERSHIP

		
	By:	 	/S/    SHIN-ICHI
YAMAMURA        
		 	 Shin-ichi Yamamura, President,
 NIF SMBC Ventures Co., Ltd.,
 General Partner of SMBC Capital No. 6 Venture Capital Investment Limited Partnership

			
	
	SMBC CAPITAL NO. 8 VENTURE CAPITAL INVESTMENT LIMITED PARTNERSHIP
		
	By:	 	/S/    SHIN-ICHI
YAMAMURA        
		 	 Shin-ichi Yamamura, President,
 NIF SMBC Ventures Co., Ltd.,
 General Partner of SMBC Capital No. 8 Venture Capital Investment Limited Partnership

			
	 “INVESTOR”
  
 NOMURA SECURITIES CO., LTD.

		
	By:	 	/S/    NORIAKI MIYANO        
		 	 Noriaki Miyano
 Senior Managing Director,
 Investment Banking Division

  

			
	 “INVESTOR”
  
 UOB JAIC VENTURE BIO INVESTMENTS LIMITED

		
	By:	 	/S/     ICHIRO KAWADA        
		 	 Ichiro Kawada
 President

			
	 “INVESTOR”
  
 ANT LEAD NO. 1 VENTURE CAPITAL INVESTMENT LIMITED PARTNERSHIP

		
	By:	 	/S/    KAZUNORI OZAKI        
		 	 Kazunori Ozaki 
 President and CEO
 Nikko antfactory K.K.

			
	 “INVESTOR”
  
 LUNNETTES, INC.

		
	By:	 	/S/    HIROSHI TANE        
		 	 Hiroshi Tane 
 President

 SCHEDULE A 
 Schedule of Investors 
 ant Lead No. 1 Venture Capital Investment Limited
Partnership 
 Aozora Investment I Venture Capital Limited Partnership 
 Aozora Investment II Venture Capital Limited Partnership 
 Aqua RIMCO Biotechnology No. 1 Investment Partnership 
 AquaRIMCO No. 10 Investment Enterprise Partnership Fund 
 AquaRIMCO No. 4 Investment Enterprise Partnership Fund 
 AquaRIMCO No. 8 Investment Enterprise Partnership Fund 
 Asahi Life Capital No. 3 Investment Enterprise Partnership 
 William F. Bennett Ph.D. 
 Bio-Sight Incubate 1st. Investment Limited Partnership 
 BIOVISION Life Science Fund I

 Board of Regents of The University of Texas System 
 CJA Pan-Pacific Rainbow No. 1 Investment Partnership 
 CSK-VC Life Science Investment Fund 
 East Gate Private Equity Fund III, L.P. 
 Fuji Green Co., Ltd. 
 Grande Vague, Limited 
 Masateru Funahashi 
 Takeshi Funahashi 
 Handai Innovation No. 1 Venture Capital Investment Limited Partnership 
 ITX International Equity Corporation 
 Brent D. Jacobs 
 JAIC America, Inc. 
 JAIC USSII No. 1, LLC 
 Japan Asia Investment Co., Ltd. 
 Hiroshi Konishi 
 Kyokuto Securities Co., Ltd. 
 Life Science Venture Fund 
 Lunnettes, Inc. 
 MHCC No. 3 Limited Liability Fund 
 Millennia 2000 Venture Capital Investment Limited Partnership 
 Mitsubishi UFJ Capital Co.,
Ltd. 
 Mizuho Capital Co., Ltd. 
 Mizuho Capital No. 1 Limited Partnership 
 Mizuho Securities Co., Ltd. 
 Mark E. Mummert 
 NIF Japan Capital Growth Fund 2005H-1 Investment Limited Partnership

 NIF Japan Capital Growth Fund 2005H-2 Investment Limited Partnership 
 NIF Japan Capital Growth Fund 2005H-3 Investment Limited Partnership 
 NIF SMBC Ventures Co., Ltd. 
 Nissay Capital No. 2 Investment Partnership 
 Nomura R&A II Venture Capital Fund
Limited Partnership 
 Nomura Securities Co., Ltd. 
 ORIX Fund No. 4 
 ORIX Fund No. 7 
 ORIX Fund No. 8 

 ORIX Fund No. 9 
 Resona Capital Co., Ltd. 
 Sankyo Sekiyu Limited 
 Jeff Schneidman 
 Shin Nihon Jitsugyo Co., Ltd. 
 SMBC Capital No. 6 Venture Capital Investment Limited Partnership 
 SMBC Capital
No. 8 Venture Capital Investment Limited Partnership 
 SOFTBANK INTERNET FUND 
 Takagi Securities Co., Ltd. 
 Akira Takashima 
 Tokio Marine and Nichido Fire Insurance Co., Ltd. 
 Toray Industries, Inc. 
 UOB JAIC Venture Bio Investments Limited 
 Venture Capital Investment Limited Partnership
NIF Global Fund 
 White Snow No. 2 Investment Limited Partnership 
 Terumi Yonemori 
 Kenneth A. ZibForm of Series B Preferred Stock Purchase Warrant

 EXHIBIT 4.3 
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED. 
 Void after 
 October 31, 2013 
 ACOLOGIX, INC. 
 WARRANT TO PURCHASE SHARES 
 This Warrant is issued to
                                        
         by Acologix, Inc., a Delaware corporation (the “Company”), pursuant to the terms of that certain Note and Warrant Purchase Agreement (the “Purchase Agreement”) of
even date herewith, in connection with the Company’s issuance to the holder of this Warrant of a Secured Convertible Promissory Note (the “Note”). 
 1.     Purchase of Shares. Subject to the terms and conditions hereinafter set forth and set forth in the Purchase Agreement, the holder of this Warrant is entitled, upon surrender of this
Warrant at the principal office of the Company (or at such other place as the Company shall notify the holder hereof in writing), to purchase from the Company up to the number of fully paid and nonassessable Shares (as defined below), that equals
the quotient obtained by dividing (a) the Warrant Coverage Amount (as defined below) by (b) the Exercise Price (as defined below). 
 2.     Definitions. Capitalized terms not otherwise defined herein shall have the meaning set forth in the Note. 
 (a)     Exercise Price. The exercise price for the Shares shall be determined as follows: (i) if the Qualified Equity Financing is consummated on or before May 15, 2004, then the
exercise price shall be the lesser of (A) the per share price paid by the other investors that purchase the Preferred Stock in the Qualified Equity Financing or (B) $0.75 (as appropriately adjusted to reflect subsequent stock
dividends, stock splits, combinations or recapitalizations); (ii) if the Qualified Equity Financing is consummated after May 15, 2004, then the exercise price shall be the lesser of (A) the per share price paid by the other
investors that purchase the Preferred Stock in the Qualified Equity Financing or (B) $0.65 (as appropriately adjusted to reflect subsequent stock dividends, stock splits, combinations or recapitalizations); or (iii) if the Qualified Equity
Financing has not yet been consummated and (A) the holder of this Warrant elects to exercise it to purchase shares of Alternative Preferred Stock or (B) a Change of Control (as defined below) is imminent and the holder of this Warrant
elects to exercise it to purchase shares of Common Stock, then the exercise price shall be $0.65 (as appropriately adjusted to reflect subsequent stock dividends, stock splits, combinations or recapitalizations). Such applicable price is herein
referred to as the “Exercise Price.” 

 (b)    Exercise Period. This Warrant shall be exercisable, in
whole or in part, during the term commencing on the date hereof and ending on the expiration of this Warrant pursuant to Section 14 hereof. 
 (c)     Warrant Coverage Amount. The term “Warrant Coverage Amount” shall mean that amount which equals twenty percent (20%) of the principal amount of the Note.

 (d)     The Shares. The term “Shares” shall mean (i) the class and series
of preferred stock issued to investors in a Qualified Equity Financing, (ii) the Alternative Preferred Stock or (iii) Common Stock, as applicable. 
 (e)     Change of Control. The term “Change of Control” shall mean (i) any merger,
consolidation, reorganization or other transaction or series of transactions relating to the Company pursuant to which the Company’s stockholders prior to such acquisition own less than fifty percent (50%) of the voting securities of the
surviving or resulting entity; or (ii) the sale of all or substantially all of the assets of the Company. 
 3.    
Method of Exercise. While this Warrant remains outstanding and exercisable in accordance with Section 1 above, the holder may exercise, in whole or in part, the purchase rights evidenced hereby. Such exercise shall be effected by:

 (i) the surrender of the Warrant, together with a notice of exercise to the Secretary of the Company at its principal
offices; and 
 (ii) the payment to the Company of an amount equal to the aggregate Exercise Price for the number of Shares
being purchased. 
 In the event that the holder is exercising this Warrant to purchase shares of Common Stock in connection with a Change of
Control, then such exercise may be made contingent upon the consummation of such Change of Control. 
 4.     Net
Exercise. In lieu of cash exercising this Warrant, the holder of this Warrant may elect to receive shares equal to the value of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the
Company together with notice of such election, in which event the Company shall issue to the holder hereof a number of Shares computed using the following formula: 
  

			
	 	  	Y (A - B)
	 X =
	  	A      

  

			
	 Where
	 	
	 X —
	 	The number of Shares to be issued to the holder of this Warrant.
	 Y —
	 	The number of Shares purchasable under this Warrant.
	 A —
	 	The fair market value of one Share.

	 	

	 	

  

 2 

			
	 B —
	 	The Exercise Price (as adjusted to the date of such calculations).

	 	

 For purposes of this Section 4, the fair market value of a Share shall mean the
average of the closing bid and asked prices of Shares quoted in the over-the-counter market in which the Shares are traded or the closing price quoted on any exchange on which the Shares are listed, whichever is applicable, as published in the
Western Edition of The Wall Street Journal for the ten (10) trading days prior to the date of determination of fair market value (or such shorter period of time during which such stock was traded over-the-counter or on such exchange). If
the Shares are not traded on the over-the-counter market or on an exchange, the fair market value shall be the price per Share that the Company could obtain from a willing buyer for Shares sold by the Company from authorized but unissued Shares, as
such prices shall be determined in good faith by the Company’s Board of Directors. 
 5.     Certificates for
Shares. Upon the exercise of the purchase rights evidenced by this Warrant, one or more certificates for the number of Shares so purchased shall be issued as soon as practicable thereafter, and in any event within thirty (30) days of the
delivery of the subscription notice. 
 6.     Issuance of Shares. The Company covenants that the Shares, when
issued pursuant to the exercise of this Warrant, will be duly and validly issued, fully paid and nonassessable and free from all taxes, liens, and charges with respect to the issuance thereof. 
 7.     Adjustment of Exercise Price and Number of Shares. The number of and kind of securities purchasable upon exercise of
this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows: 
 (a)     Subdivisions, Combinations and Other Issuances. If the Company shall at any time prior to the expiration of this Warrant subdivide the Shares, by split-up or otherwise, or combine its Shares, or issue
additional shares of its Shares as a dividend, the number of Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a
combination. Appropriate adjustments shall also be made to the purchase price payable per share, but the aggregate purchase price payable for the total number of Shares purchasable under this Warrant (as adjusted) shall remain the same. Any
adjustment under this Section 7(a) shall become effective at the close of business on the date the subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the
making of such dividend. 
 (b)     Reclassification, Reorganization and Consolidation. In case of
any reclassification, capital reorganization, or change in the capital stock of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section 7(a) above), then the Company shall make appropriate
provision so that the holder of this Warrant shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of stock and
other securities and property receivable in connection with such reclassification, reorganization, or change by a holder of the same number of Shares as were purchasable by the holder of this Warrant immediately prior to such reclassification,
reorganization, or change. In any such case appropriate provisions shall be 

  

 3 

 
made with respect to the rights and interest of the holder of this Warrant so that the provisions hereof shall thereafter be applicable with respect to any
shares of stock or other securities and property deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price per share payable hereunder, provided the aggregate purchase price shall remain the same. 

(c)     Notice of Adjustment. When any adjustment is required to be made in the number or kind of shares
purchasable upon exercise of the Warrant, or in the Exercise Price, the Company shall promptly notify the holder of such event and of the number of Shares or other securities or property thereafter purchasable upon exercise of this Warrant.

 8.     No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be
issued upon the exercise of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise Price then in effect. 
 9.     Representations of the Company. The Company represents that all corporate actions on the part of the Company, its
officers, directors and stockholders necessary for the sale and issuance of this Warrant have been taken. 
 10.    
Representations and Warranties by the Holder. The Holder, by its acceptance hereof, represents and warrants to the Company as follows: 
 (a)     This Warrant and the Shares issuable upon exercise thereof are being acquired for its own account, for investment and not with a view to, or for resale in connection with, any distribution
or public offering thereof within the meaning of the Securities Act of 1933, as amended (the “Act”). Upon exercise of this Warrant, the Holder shall, if so requested by the Company, confirm in writing, in a form satisfactory to
the Company, that the securities issuable upon exercise of this Warrant are being acquired for investment and not with a view toward distribution or resale. 
 (b)     The Holder understands that the Warrant and the Shares have not been registered under the Act by reason of
their issuance in a transaction exempt from the registration and prospectus delivery requirements of the Act pursuant to Section 4(2) thereof, and that they must be held by the Holder indefinitely, and that the Holder must therefore bear the
economic risk of such investment indefinitely, unless a subsequent disposition thereof is registered under the Act or is exempted from such registration. The Holder further understands that the Warrant Shares have not been qualified under the
California Securities Law of 1968 (the “California Law”) by reason of their issuance in a transaction exempt from the qualification requirements of the California Law pursuant to Section 25102(f) thereof, which exemption
depends upon, among other things, the bona fide nature of the Holder’s investment intent expressed above. 
 (c)     The Holder has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the purchase of this Warrant and the Shares purchasable pursuant to the
terms of this Warrant and of protecting its interests in connection therewith. 
 (d)     The Holder is
able to bear the economic risk of the purchase of the Shares pursuant to the terms of this Warrant. 
  

 4 

 (e)     The Holder is an “accredited investor” as such term
is defined in Rule 501 of Regulation D promulgated under the Act. 
 11.     Restrictive Legend. 
 The Shares (unless registered under the Act) shall be stamped or imprinted with a legend in substantially the following form: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION
THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
COPIES OF THE AGREEMENT COVERING THE PURCHASE OF THESE SHARES AND RESTRICTING THEIR TRANSFER MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY AT THE PRINCIPAL EXECUTIVE
OFFICES OF THE COMPANY. 
 12.     Warrants Transferable. Subject to compliance with the terms and conditions of
this Section 12, this Warrant and all rights hereunder are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes), upon surrender of this Warrant properly endorsed or accompanied by written
instructions of transfer. With respect to any offer, sale or other disposition of this Warrant or any Shares acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or Shares, the holder hereof agrees to give written
notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such holder’s counsel, or other evidence, if requested by the Company, to the effect that such offer, sale or other disposition may
be effected without registration or qualification (under the Act as then in effect or any federal or state securities law then in effect) of this Warrant or the Shares and indicating whether or not under the Act certificates for this Warrant or the
Shares to be sold or otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order to ensure compliance with such law. Upon receiving such written notice and reasonably satisfactory opinion or other
evidence, if so requested, the Company, as promptly as practicable, shall notify such holder that such holder may sell or otherwise dispose of this Warrant or such Shares, all in accordance with the terms of the notice delivered to the Company. If a
determination has been made pursuant to this Section 12 that the opinion of counsel for the holder or other evidence is not reasonably satisfactory to the Company, the Company shall so notify the holder promptly with details thereof after such
determination has been made. Each certificate representing this Warrant or the Shares transferred in accordance with this Section 12 shall bear a legend as to the applicable restrictions on transferability in order to ensure compliance with
such laws, unless in the aforesaid opinion of counsel for the holder, such legend is not required in order to ensure compliance with such laws. The Company may issue stop transfer instructions to its transfer agent in connection with such
restrictions. 
 13.     Rights of Stockholders. No holder of this Warrant shall be entitled, as a Warrant holder,
to vote or receive dividends or be deemed the holder of the Shares or any other securities of 

  

 5 

 
the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the
holder of this Warrant, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any
corporate action (whether upon any recapitalization, issuance of stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights
or otherwise until the Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. 
 14.     Expiration of Warrant; Notice of Certain Events Terminating This Warrant. 
  

	 	(a)	This Warrant shall expire and shall no longer be exercisable upon the earlier to occur of: 

 (i) 5:00 p.m., California local time, on October 31, 2013; 
 (ii) Any Change of Control; or 
 (iii) The initial public offering of the Company’s Common Stock. 
  

	 	(b)	The Company shall provide at least ten (10) days prior written notice of any event set forth in Section 14(a)(ii) or (iii). 

 15.     Notices. All notices and other communications required or permitted hereunder shall be in writing, shall be effective
when given, and shall in any event be deemed to be given upon receipt or, if earlier, (a) five (5) days after deposit with the U.S. Postal Service or other applicable postal service, if delivered by first class mail, postage prepaid,
(b) upon delivery, if delivered by hand, (c) one business day after the business day of deposit with Federal Express or similar overnight courier, freight prepaid or (d) one business day after the business day of facsimile
transmission, if delivered by facsimile transmission with copy by first class mail, postage prepaid, and shall be addressed (i) if to the Holder, at the Holder’s address as set forth on the Schedule of Investors to the Purchase Agreement,
and (ii) if to the Company, at the address of its principal corporate offices (attention: President), with a copy to Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, California 94304, Attn: Mario M. Rosati, Esq.
or at such other address as a party may designate by ten days advance written notice to the other party pursuant to the provisions above. 
 16.     “Market Stand-Off” Agreement. Holder hereby agrees that, during the period of duration specified by the Company and an underwriter of common stock or other securities of the Company, following
the effective date of a registration statement of the Company filed under the Act, it shall not, to the extent requested by the Company and such underwriter, directly or indirectly sell, offer to sell, contract to sell (including, without
limitation, any short sale), grant any option to purchase or otherwise transfer or dispose of (other than to donees who agree to be similarly bound) any securities of the Company held by it at any time during such period except common stock included
in such registration; provided, however, that: 
 (a) all officers and directors of the Company enter into similar
agreements; 
  

 6 

 (b)     the Company obtains from persons who hold five percent (5%) or greater
of the Company’s outstanding capital stock, a lock-up agreement similar to that set forth in this Section 16; and 
 (c)     such market stand-off time period shall not exceed one hundred eighty (180) days for the Company’s initial public offering. 
 Holder agrees to provide to the other underwriters of any public offering such further agreements as such underwriter may reasonably request in connection with this market stand-off agreement, provided that the terms
of such agreements are substantially consistent with the provisions of this Section 16. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Registrable Securities of each Holder (and
the shares or securities of every other person subject to the foregoing restriction) until the end of such period. 
 Notwithstanding the
foregoing, the obligations described in this Section 16 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms which may be promulgated in the future, or a registration relating
solely to an SEC Rule 145 transaction. 
 17.     Registration Rights Agreement. The registration rights of the
Holder (including Holders’ successors) with respect to the Common Stock issuable upon conversion of the Shares issuable upon exercise of this Warrant will be the same as granted to the holders of Shares issued in the Qualified Equity Financing.

 18.     Governing Law. This Warrant and all actions arising out of or in connection with this Agreement shall
be governed by and construed in accordance with the laws of the State of California, without regard to the conflicts of law provisions of the State of California or of any other state. 
 19.     Rights and Obligations Survive Exercise of Warrant. Unless otherwise provided herein, the rights and obligations of
the Company, of the holder of this Warrant and of the holder of the Shares issued upon exercise of this Warrant, shall survive the exercise of this Warrant. 
 Issued October 31, 2003. 
  

			
	 ACOLOGIX, INC.
 a Delaware corporation

		
	 By:   
	 	  
		 	 Yoshinari Kumagai
 President & CEO

  

 7 

 EXHIBIT A 
 NOTICE OF EXERCISE 
  

	 	TO:	Acologix, Inc. 

 6121 Hollis Street 
 Emeryville, CA 94608 
 Attention: President

 1. The undersigned hereby elects to purchase
                         Shares of
                             pursuant to the terms of the attached Warrant. 
 2. Method of Exercise (Please initial the applicable blank): 
  

	 	—	The undersigned elects to exercise the attached Warrant by means of a cash payment, and tenders herewith payment in full for the purchase price of the shares being purchased,
together with all applicable transfer taxes, if any. 

  

	 	—	The undersigned elects to exercise the attached Warrant by means of the net exercise provisions of Section 4 of the Warrant. 

 3. Please issue a certificate or certificates representing said Shares in the name of the undersigned or in such other name as is specified below:

  

	
	
	  
	(Name)
	
	  
	
	  
	(Address)

 4. The undersigned hereby represents and warrants that the aforesaid Shares are being acquired for
the account of the undersigned for investment and not with a view to, or for resale, in connection with the distribution thereof, and that the undersigned has no present intention of distributing or reselling such shares and all representations and
warranties of the undersigned set forth in Section 10 of the attached Warrant (including Section 10 (e) thereof) are true and correct as of the date hereof. 
  

					
			
		 		 	  
		 		 	 (Signature)

			
		 		 	  
		 		 	 (Name)

			
	  	 		 	  
	(Date)	 		 	 (Title)

 EXHIBIT B 
 FORM OF TRANSFER 
 (To be signed only upon transfer of Warrant) 
 FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto
                                        
                                     the right represented by the
attached Warrant to purchase                              shares of
                                        
of Acologix, Inc. to which the attached Warrant relates, and appoints Wilson Sonsini Goodrich & Rosati, P.C., to transfer such right on the books of Acologix, Inc., with full power of substitution in the premises. 
  

			
		
	Dated:	 	  

  

			
		
	  	 	  
	
	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
		
	Address:	 	  
		 	  
		 	  

  

	
	 Signed in the presence of:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]